CD63 and Duchenne muscular dystrophy: To develop a treatment for Duchenne muscular dystrophy (DMD), a common myopathic disease in children caused by loss of a functional dystrophin protein, the inhibitory domain of myostatin propeptide was fused with the second extracellular loop of CD63, which significantly improved its serum stability and delivery efficiency.